Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: medwriter who wrote (850)	5/18/1998 8:18:00 PM
From: Robert Florin	Respond to of 1029

Anyone interested in today's announcement. Excellent news for both patients and investors. The news is good both because it will be the preferable first line treatment, and because the length of treatment will be extensive. This results in the unusual position of an anti-infective agent being used on an ongoing basis. Should accrue nicely to the bottom line very quickly and to a much greater extent than Panic's recent predictions. I believe he thought that there would be 100,000 patients in active treatment. Given the size of the potential pool and the absence of alternatives, I think that number is way, way, way too low. I remain very hopeful on ICN's prospects for all the reasons stated before and this new excellent information